Critical issues around testing for B12 levels In 1849, Thomas Addison described a lethal condition in which sufferers developed severe neurological symptoms (pins and needles, numbness, ataxia and eventually paralysis, psychosis and glossitis (sore tongue))
Published pharmacokinetic data for both peptides remain limited
This final recovery phase involves cautious return to full training, guided by symptom resolution and functional testing
Fermented foods (such as tempeh), nori, spirulina, chlorella algae, and unfortified nutritional yeast cannot be relied upon as adequate or practical sources of B-12.39,40 Vegans must regularly consume reliable sourcesmeaning B-12 fortified foods or B-12 containing supplementsor they could become deficient, as shown in case studies of vegan infants, children, and adults
References Stanley, T
Critical safety considerations for laboratory use include potential immunogenicity concernswith peptide therapeutics commonly showing injection site reactions (20-40% with subcutaneous administration) and possible antidrug antibody formationalong with theoretical concerns that pro-angiogenic properties could potentially influence experimental tumor models, requiring appropriate controls in oncology-related research
